MX2023004169A - Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas. - Google Patents

Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.

Info

Publication number
MX2023004169A
MX2023004169A MX2023004169A MX2023004169A MX2023004169A MX 2023004169 A MX2023004169 A MX 2023004169A MX 2023004169 A MX2023004169 A MX 2023004169A MX 2023004169 A MX2023004169 A MX 2023004169A MX 2023004169 A MX2023004169 A MX 2023004169A
Authority
MX
Mexico
Prior art keywords
cell
tcr
gene expression
modified
nucleic acid
Prior art date
Application number
MX2023004169A
Other languages
English (en)
Inventor
Carl H June
Yangbing Zhao
Jiangtao Ren
Xiaojun Liu
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2023004169A publication Critical patent/MX2023004169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención está relacionada a composiciones y métodos para generar una célula T modificada con un ácido nucleico capaz de regular a la baja la expresión genética endógena de un gen seleccionado del grupo que consiste en una cadena TCR a, una cadena TCR ß, beta-2 microglobulina, una molécula HLA, CTLA-4, PD1, y FAS y adicionalmente comprende un ácido nucleico que codifica para un receptor de células T modificado (TCR) que comprende afinidad para un antígeno de superficie sobre una célula objetivo o un ácido nucleico electroporado que codifica para un receptor de antígeno quimérico (CAR); también incluidos están métodos y composiciones farmacéuticas que comprenden la célula T modificada para terapia adoptiva y tratar una condición, tal como una enfermedad autoinmune.
MX2023004169A 2014-10-31 2017-04-28 Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas. MX2023004169A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073651P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
MX2023004169A true MX2023004169A (es) 2023-05-03

Family

ID=55858177

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005698A MX2017005698A (es) 2014-10-31 2015-10-15 Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
MX2023004169A MX2023004169A (es) 2014-10-31 2017-04-28 Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005698A MX2017005698A (es) 2014-10-31 2015-10-15 Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.

Country Status (12)

Country Link
US (6) US11208661B2 (es)
EP (3) EP4219725A3 (es)
JP (4) JP6879910B2 (es)
KR (3) KR102546296B1 (es)
CN (3) CN107249606A (es)
AU (3) AU2015339744B2 (es)
BR (1) BR112017008693A2 (es)
CA (2) CA2964948A1 (es)
EA (1) EA201790953A1 (es)
HK (1) HK1243332A1 (es)
MX (2) MX2017005698A (es)
WO (2) WO2016069282A1 (es)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3115457B1 (en) 2014-03-05 2019-10-02 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP6879910B2 (ja) 2014-10-31 2021-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
CN113713091A (zh) 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
KR20180020125A (ko) * 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
KR102648489B1 (ko) 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
WO2016183041A2 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
US11179448B2 (en) 2015-07-16 2021-11-23 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
JP6816133B2 (ja) 2015-10-05 2021-01-20 プレシジョン バイオサイエンシズ，インク． 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
ES2914623T3 (es) 2015-11-27 2022-06-14 Univ Kobe Nat Univ Corp Método para convertir una secuencia genómica de una planta monocotiledónea en la que una base de ácido nucleico en la secuencia de ADN diana se convierte de manera específica y el complejo molecular utilizado en el mismo
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109844116A (zh) 2016-07-05 2019-06-04 约翰霍普金斯大学 包括使用h1启动子对crispr指导rna的改进的组合物和方法
WO2018009525A1 (en) * 2016-07-05 2018-01-11 The Johnson Hopkins University Crispr/cas9-based compositions and methods for treating cancer
CN106191062B (zh) * 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 一种tcr-/pd-1-双阴性t细胞及其构建方法
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN106480097A (zh) * 2016-10-13 2017-03-08 南京凯地生物科技有限公司 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
CN106399375A (zh) * 2016-08-31 2017-02-15 南京凯地生物科技有限公司 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
CN110139873A (zh) * 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
GB2607227B (en) * 2016-10-27 2023-05-10 Intima Bioscience Inc Viral methods of T cell therapy
KR102584628B1 (ko) * 2016-11-07 2023-10-04 제노비에 에이비 T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
AU2017352591A1 (en) 2016-11-07 2019-05-02 Genovie Ab A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells
GB201622044D0 (en) * 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110268050A (zh) * 2017-01-10 2019-09-20 综合医院公司 经修饰的t细胞和它们的使用方法
WO2018132508A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Methods and compositions relating to ex vivo culture and modulation of t cells
US11555178B2 (en) * 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
AU2018234640B2 (en) * 2017-03-14 2024-03-14 Juno Therapeutics, Inc. Methods for cryogenic storage
KR20190130608A (ko) * 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
EP4029943A1 (en) * 2017-05-08 2022-07-20 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
CN110944652A (zh) * 2017-06-12 2020-03-31 爱莫里大学 T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途
CA3067382A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
CN109963944A (zh) * 2017-06-20 2019-07-02 江苏恒瑞医药股份有限公司 体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA
WO2018236909A1 (en) * 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology T-MODIFIED LYMPHOCYTE RECEPTORS AND METHODS OF USE IN INFLAMMATORY RESPONMS MODULATION AND ATHEROSCLEROSIS TREATMENT
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
EP3441461A1 (en) * 2017-08-11 2019-02-13 Baylor College of Medicine Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
WO2019047932A1 (zh) * 2017-09-08 2019-03-14 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
WO2019052577A1 (zh) * 2017-09-18 2019-03-21 博雅辑因（北京）生物科技有限公司 一种基因编辑t细胞及其用途
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CN109517820B (zh) * 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
CN107630006B (zh) * 2017-09-30 2020-09-11 山东兴瑞生物科技有限公司 一种制备tcr与hla双基因敲除的t细胞的方法
CA3080546A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019073965A1 (ja) 2017-10-10 2019-04-18 国立大学法人広島大学 エフェクターＴ細胞（Ｔｅｆｆ）抗原受容体を用いた抗原特異的制御性Ｔ細胞（Ｔｒｅｇ）の作出技術
TWI814746B (zh) 2017-10-10 2023-09-11 國立大學法人廣島大學 使用鉑talen之t細胞受體之完全置換技術
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN107827989A (zh) * 2017-10-18 2018-03-23 银丰生物工程集团有限公司 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
BR112020008201A2 (pt) * 2017-10-27 2020-10-06 The Regents Of The University Of California substituição-alvo de receptores de células t endógenos
AU2018357861A1 (en) 2017-10-30 2020-06-11 Adoc Ssf, Llc Primary cell gene editing
CN107916269B (zh) * 2017-11-17 2020-12-11 山东兴瑞生物科技有限公司 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
WO2019106163A1 (en) * 2017-12-01 2019-06-06 Cellectis Reprogramming of genetically engineered primary immune cells
WO2019118508A1 (en) * 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
EP3724321A4 (en) * 2017-12-13 2021-09-01 Janssen Biotech, Inc. GENETICALLY MODIFIED IMMORTALIZED CAR-T LYMPHOCYTES TO ELIMINATE T-LYMPHOCYTE RECEPTOR EXPRESSION AND BETA 2-MICROGLOBULIN
WO2019129851A1 (en) * 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
CN108559760A (zh) * 2018-01-09 2018-09-21 陕西师范大学 基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
KR20210141768A (ko) 2018-01-12 2021-11-23 주식회사 큐로셀 이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
US20200339687A1 (en) * 2018-01-19 2020-10-29 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
EP3775229A4 (en) * 2018-03-27 2021-12-15 The Trustees Of The University Of Pennsylvania MODIFIED IMMUNE CELLS WITH IMPROVED FUNCTIONS AND SCREENING PROCEDURES FOR THIS
EP3775214A2 (en) 2018-03-30 2021-02-17 University of Geneva Micro rna expression constructs and uses thereof
AU2019248644A1 (en) 2018-04-02 2020-10-22 Adoc Ssf, Llc Peptide-MHC compacts
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
MX2020010461A (es) 2018-04-05 2021-01-15 Juno Therapeutics Inc Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
WO2019200122A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
CN108490174B (zh) * 2018-04-18 2022-06-24 上海尚珞生物医药科技有限公司 检测car-t细胞的方法及其应用
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
EP3794130A4 (en) 2018-05-16 2022-07-27 Synthego Corporation METHODS AND SYSTEMS FOR DESIGN AND USE OF GUIDE RNA
CN110616188B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种通用型car-t细胞及其制备方法和应用
EP3833743B1 (en) * 2018-08-08 2024-01-24 NantBio, Inc. Recombinant cd1-restricted t cells for treating tuberculosis
CN110904045A (zh) * 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CN112739817A (zh) * 2018-09-21 2021-04-30 佧珐药业有限公司 表达有嵌合受体的t细胞
US20210395774A1 (en) * 2018-09-25 2021-12-23 Microbial Chemistry Research Foundation Novel virus vector and methods for producing and using same
JP2022502037A (ja) 2018-09-28 2022-01-11 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
CN109295106B (zh) * 2018-09-30 2020-07-24 北京鼎成肽源生物技术有限公司 一种hafft1细胞
SG11202103571XA (en) * 2018-10-16 2021-05-28 Intellia Therapeutics Inc Compositions and methods for immunotherapy
CN112955472A (zh) * 2018-11-07 2021-06-11 克里斯珀医疗股份公司 抗ptk7免疫细胞癌症疗法
US20210292429A1 (en) * 2018-11-07 2021-09-23 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
CN111788302A (zh) * 2018-11-21 2020-10-16 南京北恒生物科技有限公司 修饰的t细胞及其用途
BR112021012172A2 (pt) 2018-12-12 2021-08-31 Kite Pharma, Inc. Receptores de antígenos quiméricos e de célula t e métodos de uso
CN109722437B (zh) * 2018-12-29 2020-01-07 广州百暨基因科技有限公司 一种通用型car-t细胞及其制备方法和用途
CN109652378B (zh) * 2018-12-29 2020-04-24 广州百暨基因科技有限公司 一种功能增强的通用型car-t细胞及其制备方法和用途
AU2020208616A1 (en) * 2019-01-16 2021-08-12 Beam Therapeutics Inc. Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
CN113557036A (zh) 2019-01-18 2021-10-26 奥泽生物疗法公司 基因编辑以改善关节功能
AU2020221229A1 (en) 2019-02-12 2021-09-02 Adoc Ssf, Llc Compositions and methods for identification of antigen specific T cells
WO2020172571A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN109913501B (zh) * 2019-03-01 2022-08-16 华东师范大学 一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法
CN111676195A (zh) * 2019-03-11 2020-09-18 北京卡替医疗技术有限公司 一种治疗t细胞肿瘤的ucar免疫细胞
US20220152109A1 (en) * 2019-03-18 2022-05-19 Ludwig Institute For Cancer Research Ltd A2/ny-eso-1 specific t cell receptors and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US20200317780A1 (en) * 2019-03-21 2020-10-08 Allogene Therapeutics, Inc. METHODS FOR ENHANCING TCRab+ CELL DEPLETION
KR20210148293A (ko) 2019-04-03 2021-12-07 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN112430575B (zh) * 2019-08-26 2024-01-19 深圳市菲鹏生物治疗股份有限公司 通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
MX2022002763A (es) * 2019-09-06 2022-04-06 Crispr Therapeutics Ag Linfocitos t modificados por ingenieria genetica que tienen persistencia mejorada en cultivo.
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
TW202132333A (zh) * 2019-11-13 2021-09-01 瑞士商Ｃｒｉｓｐｒ治療公司 製造可表達嵌合抗原受體的ｔ細胞製法
AU2020382017A1 (en) * 2019-11-13 2022-05-12 Crispr Therapeutics Ag Methods of manufacturing CAR-T cells
US20230009232A1 (en) * 2019-11-20 2023-01-12 Cartherics Pty. Ltd. Method for providing immune cells with enhanced function
US20210155924A1 (en) * 2019-11-27 2021-05-27 Stitch Bio, Llc Methods and compositions for inducing tumor cell death
CN113061580B (zh) * 2020-01-02 2022-09-06 宁波茂行生物医药科技有限公司 一种经修饰的免疫效应细胞及其制备方法
CN114929867A (zh) * 2020-01-21 2022-08-19 苏州克睿基因生物科技有限公司 一种经修饰的免疫效应细胞及其用途
KR20210095586A (ko) * 2020-01-23 2021-08-02 주식회사 강스템바이오텍 off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
JP2023515270A (ja) * 2020-04-21 2023-04-12 テンパス・ラボズ・インコーポレイテッド Ｔｃｒ／ｂｃｒプロファイリング
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN113684258A (zh) * 2020-05-18 2021-11-23 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
US20230250149A1 (en) * 2020-06-25 2023-08-10 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022012531A1 (zh) * 2020-07-14 2022-01-20 苏州克睿基因生物科技有限公司 一种经修饰的免疫细胞的制备方法
CN116113696A (zh) * 2020-07-16 2023-05-12 奥泽生物疗法公司 基因编辑以改善关节功能
CN112266899A (zh) * 2020-10-26 2021-01-26 北京卡替医疗技术有限公司 修饰的免疫细胞及其用途
WO2022106731A1 (en) * 2020-11-23 2022-05-27 Ludwig-Maximilians-Universität München Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN112899227B (zh) * 2021-01-14 2022-09-13 中国科学院微生物研究所 一种调控辅助性t细胞功能的方法
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
KR20230151518A (ko) * 2021-03-04 2023-11-01 알로젠 테라퓨틱스 인코포레이티드 치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
CN117413054A (zh) * 2021-03-08 2024-01-16 宾夕法尼亚大学董事会 评估和治疗t细胞功能障碍的组合物和方法
AU2022343300A1 (en) 2021-09-10 2024-04-18 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
WO2023055942A1 (en) * 2021-09-29 2023-04-06 The Johns Hopkins University Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN113980907B (zh) * 2021-12-24 2022-03-15 山东兴瑞生物科技有限公司 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
CN114591963B (zh) * 2022-05-10 2022-07-19 上海优替济生生物医药有限公司 sgRNA及利用其构建GM-CSF(-)细胞的方法
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA120409A (en) 1909-05-13 1909-09-07 Hiram Lucas Piper Signal lamp
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
DK0663817T3 (da) 1993-08-10 2000-03-13 Gore & Ass Celleindkapslingsindretning
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6143291A (en) 1995-05-04 2000-11-07 Us Navy Methods for modulating T cell survival by modulating bcl-XL protein level
JPH10503964A (ja) 1995-06-07 1998-04-14 ゴア ハイブリッド テクノロジーズ，インコーポレイティド 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
DK1259265T3 (da) 2000-03-03 2011-07-11 Genetronics Inc Nukleinsyre-formuleringer til afgivelse af gener
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
EP1660534A2 (en) 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
JP2009518044A (ja) 2005-12-07 2009-05-07 ジェネトロニクス，インコーポレイティド 可変容積エレクトロポレーションチャンバー及びその使用方法
PT2016102E (pt) * 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
WO2007150054A2 (en) 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
AU2008233051B2 (en) 2007-03-30 2014-04-10 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009029883A2 (en) * 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating t cells
EP3450545B1 (en) * 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
TWI686202B (zh) 2010-08-04 2020-03-01 幹細胞生物科技公司 體幹細胞
ME02810B (me) 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
KR102062407B1 (ko) 2010-12-09 2020-01-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
ES2723181T3 (es) 2011-07-29 2019-08-22 Univ Pennsylvania Receptores de conmutación coestimulante
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
CN104159909A (zh) * 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
JP2015514421A (ja) 2012-04-17 2015-05-21 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォーコマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
WO2013177247A1 (en) 2012-05-22 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-ny-eso-1 t cell receptors
EP3964567A1 (en) 2012-05-25 2022-03-09 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EA038924B1 (ru) 2012-05-25 2021-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции рнк-специфической модификации днк-мишени и рнк-специфической модуляции транскрипции
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
AU2013312838B2 (en) * 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014207618A1 (en) 2013-01-16 2015-08-06 Emory University Cas9-nucleic acid complexes and uses related thereto
CN105283539A (zh) 2013-03-12 2016-01-27 桑格摩生物科学股份有限公司 用于hla的修饰的方法和组合物
JP6464140B2 (ja) 2013-03-13 2019-02-06 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
US9587237B2 (en) * 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014153470A2 (en) * 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
MX2015015638A (es) 2013-05-13 2016-10-28 Cellectis Metodos para diseñar celulas t altamente activas para inmunoterapia.
CA2910489A1 (en) * 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US9890393B2 (en) * 2013-05-29 2018-02-13 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system
KR102228828B1 (ko) * 2014-03-11 2021-03-16 셀렉티스 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
AU2015245469B2 (en) 2014-04-11 2020-11-12 Cellectis Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
EP3800248A3 (en) 2014-04-18 2021-08-04 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
WO2016054086A1 (en) 2014-09-30 2016-04-07 The Regents Of The University Of California Codon-optimized lentiviral vector for stem cell reprogramming
WO2016057850A1 (en) * 2014-10-09 2016-04-14 Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
JP6879910B2 (ja) 2014-10-31 2021-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
KR20180020125A (ko) * 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy

Also Published As

Publication number Publication date
US20170335331A1 (en) 2017-11-23
JP2018500006A (ja) 2018-01-11
KR20170074245A (ko) 2017-06-29
EP3215168A1 (en) 2017-09-13
KR102546296B1 (ko) 2023-06-21
EP4219725A3 (en) 2023-08-30
JP6879910B2 (ja) 2021-06-02
CN107249606A (zh) 2017-10-13
EP3215168A4 (en) 2018-08-15
EP3215166A4 (en) 2018-12-05
AU2015339743A1 (en) 2017-04-27
JP2017535261A (ja) 2017-11-30
BR112017008693A2 (pt) 2018-02-27
US20180312848A1 (en) 2018-11-01
CA2964948A1 (en) 2016-05-06
CN107206024B (zh) 2021-12-03
JP2021058196A (ja) 2021-04-15
US11203758B2 (en) 2021-12-21
WO2016069283A1 (en) 2016-05-06
JP2023037006A (ja) 2023-03-14
HK1243332A1 (zh) 2018-07-13
US20200407728A1 (en) 2020-12-31
KR20230098910A (ko) 2023-07-04
MX2017005698A (es) 2017-06-29
AU2015339743B2 (en) 2020-11-05
CA2964953A1 (en) 2016-05-06
US11208661B2 (en) 2021-12-28
EP4219725A2 (en) 2023-08-02
CN114836385A (zh) 2022-08-02
KR20170075013A (ko) 2017-06-30
AU2015339744A1 (en) 2017-04-27
AU2021200118B2 (en) 2023-09-21
US20170290858A1 (en) 2017-10-12
EA201790953A1 (ru) 2017-10-31
AU2015339744B2 (en) 2021-03-25
EP3215166A1 (en) 2017-09-13
EP3215166B1 (en) 2024-04-24
AU2021203981A1 (en) 2021-07-15
AU2015339743C1 (en) 2021-04-22
WO2016069282A1 (en) 2016-05-06
AU2021200118A1 (en) 2021-03-25
EP3215168B1 (en) 2023-08-02
US20220154190A1 (en) 2022-05-19
US20220145306A1 (en) 2022-05-12
CN107206024A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
MX2023004169A (es) Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
PH12018500965A1 (en) Methods and compositions for gene editing in hematopoietic stem cells
BR112018067698A2 (pt) células modificadas para imunoterapia
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
MX2022012082A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
MX2022007894A (es) Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
WO2014145252A3 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MY181834A (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
MX2019012360A (es) Composiciones y metodos mejorados de celulas t.
MX2017001013A (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
BR112015021819A2 (pt) Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19
WO2014022423A3 (en) Hla g-modified cells and methods
MX2019006286A (es) Metodos para determinar la dosificacion en la terapia celular.
JP2017538401A5 (es)
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2020005495A (es) Anticuerpo anti-vista y uso del mismo.